Icosavax, Inc. (Nasdaq: ICVX), relating to its proposed sale to AstraZeneca. Under the terms of the agreement, ICVX shareholders are expected to receive $15.00 in cash and one non-tradeable CVR worth up to $5.00 per share they own.
Icosavax, Inc. (Nasdaq: ICVX), relating to its proposed sale to AstraZeneca. Under the terms of the agreement, ICVX shareholders are expected to receive $15.00 in cash and one non-tradeable CVR worth up to $5.00 per share they own.